$185 Million available via Pharmaceutical Benefit Plan Settlements
There are typically several active lawsuits and/or class action settlements that fall into the category of “pharmaceutical benefit plan settlements.” Under these cases, it is generally alleged that businesses with self-insured health plans overpaid for drugs purchased on behalf of their employees due to artificially inflated and/or stabilized prices.
The prices were allegedly manipulated as a result of anti-competitive practices undertaken by the drug manufacturers. The number of these opportunities in any given year varies, but there can be several available at the same time.
Immediately Available Settlement(s):
Date Range: Sept. 2012 - April 2020
Settlement Fund: $145 Million
Filing Deadline: 10/11/2022
Settlement Overview: This settlement resolves allegations that Defendant Ranbaxy manipulated the U.S. Food and Drug Administration’s generic-drug approval process, limiting competition and violating antitrust laws. A fund has been created for third party payors, covering three drugs: antiviral drug Valcyte, high blood pressure drug Diovan, and reflux medication Nexium.
Eligible Locations: All organizations located within the United States.
Eligible Drug (s): Brand/Generic Diovan, Brand/Generic Valycte, Generic Nexium
Date Range: April 2016-Feb. 2022
Settlement Fund: $25 Million
Filing Deadline: 11/30/2022
Settlement Overview: This settlement resolves allegations that Defendants violated federal antitrust laws, causing consumers and third party payors to pay supracompetitive prices for infliximab (Remicade)-a drug used to treat autoimmune disorders including rheumatoid arthritis and Crohn’s disease.
Eligible Locations: To be a member of the Settlement Class, you must have purchased, paid and/or provided reimbursement for some or all of the purchase price of Remicade that was purchased in any of the eligible states and territories below:
Arizona, Arkansas, California, District of Columbia, Florida, Hawaii, Iowa, Kansas, Maine, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin.
Eligible Drug: Remicade
Opana ER Settlement
Date Range: April 2011-Sept. 2018
Settlement Fund: $15 million
Filing Deadline: 1/5/2023
Settlement Overview: A settlement fund has been created to resolve allegations Defendant blocked competition to its drug Opana ER, an opioid pain medication, by entering into a series of anticompetitive agreements which prevented less expensive generic versions becoming available to the class.
Eligible Locations: To be a member of the Settlement Class, you must have indirectly purchased, paid and/or provided reimbursement for some or all of the purchase price of Remicade that was purchased in any of the eligible states and territories below:
Arizona*, California, Florida, Hawaii, Iowa, Maine, Massachusetts*, Michigan, Minnesota, Missouri, Mississippi*, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Pennsylvania, Oregon, South Dakota, Tennessee, Utah, Vermont, West Virginia, Wisconsin, and the District of Columbia.
* With respect to Arizona, Massachusetts, and Mississippi, Class Members must have purchased, paid for, and/or provided reimbursement for some or all of the purchase price of brand or generic Opana ER from June 4, 2011, through September 2018.
Eligible Drug: Brand or generic Opana ER, in the 5, 10, 20, 30, or 40 mg strengths, sold by Endo or Impax
Recommended Next Steps Data is often required to complete your claim for settlements in this category. Connect us with a member of your Benefits Department so an MCAG representative can describe the information that is necessary to complete your claim for these pharmaceutical settlements. We typically only need a 5 to 10 minute call. We will quickly review the process so we can efficiently obtain necessary information from your Pharmacy Benefit Manager (i.e. CVS Caremark, Express Scripts, OptumRX) to pursue current and future pharmaceutical settlements.
Eligible contracted clients can expect to be contacted by an MCAG representative to review and assist with gathering the necessary information for these settlements.
MCAG is not the Settlement/Class Administrator, and this is not an official settlement website.
Need more information? CLICK HERE to complete our contact form and an MCAG representative will respond shortly.